This paper is only available as a PDF. To read, Please Download here.
Abstract
The aim of this study is to investigate immunoreactivity for p53, p21 and metallothionein in diffuse malignant pleural mesothelioma (DMPM) and to determine the relationships between the age, sex, asbestos exposure time, survival of DMPM patients with environmental asbestos exposure and immunoreactivity to p53, p21 and metallothionein.
Sixty-seven histopathologically-confirmed DMPMs, 38 of whom had environmental and 29 had occupational asbestos exposure, were included. The tumour tissue samples were immunostained with antibodies against p53, p21 and metallothionein. Epidemiological data and the survival times for the DMPM patients with environmental asbestos exposures were obtained from hospital records. Thirty-three per cent of the DMPMs were positive for p53, 35% for p21 and 52% for metallothionein. There was no statistical difference between the histological subtypes of DMPM in terms of immunoreactivity for p53, p21 and metallothionein. For p21 and metallothionein there was a statistically significant difference between the exposure characteristics: patients with environmental asbestos exposure had shown more immunopositivity. There were statistically significant differences between age groups and between asbestos exposure times for metallothionein, and between asbestos exposure times and p21. The patients with positive immunostaining had longer exposure times and were older than those having negative immunostaining. The differences between survival of the patients were not statistically significant in terms of the immunohistochemical results for p53, p21 and metallothionein.
Keywords
References
References
- Overview of current issues with respect to mesothelioma.Eur Respir Rev. 1993; 3: 12-17
- Tumours of the pleura.in: Murray JF Nadel JA Testbook of Respiratory Medicine. 2. W.B. Saunders, Philedelphia1994: 2222-2234
- Malignant mesothelioma: clinical characteristics, asbestos minerology and chromosomal absormalities of 42 patients.Eur J Cancer. 1992; 28: 1373-1379
- Molecular pathobiology and immunology of malignant mesothelioma.J Pathol. 1996; 178: 369-378
- The pathogenesis of malignant and nonmalignant serosal lesions in body cavities cosequent to asbestos exposure.in: Jauren MC Bignon J Mesothelial Cell and Mesothelioma. Marcel Dekker, New York1994: 79-101
- Genetic and molecular changes of human lung cancer.in: Fishman AP Fisherman's Pulmonary Diseases and Disorders. 2. McGraw Hill, New York1998: 1695-1705
- Genetic factors in the aetiology of malignant mesothelioma.Eur J Cancer. 1995; 31: 1741-1747
- Genetic alterations of the p53 gene are a feature of malignant mesothelioma.Cancer Res. 1991; 51: 5410-5416
- Chromosomal abnormalities in human malignant mesothelioma.in: Jauren MC Bignon J Mesothelial Cell and Mesothelioma. Marcel Dekker, New York1994: 245-253
- Environmental asbestos exposure and malignant pleural mesothelioma.Respir Med. 1999; 93: 349-355
- p53 immunostaining in the distinction between benign and malignant mesothelial proliferation using formalin-fixed paraffin sections.J Pathol. 1992; 168: 377-381
- The p53 tumour supressor gene.Nature. 1991; 351: 453-456
- Prognostic factors in resectable non-small cell lung cancer.Thorax. 1996; 51: 638-646
- p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke.Am J Respir Crit Care Med. 1994; 150: 528-533
- The relationship of p53 immunostaining to survival in carcinoma of the lung.Br J Cancer. 1992; 66: 735-738
- Clinical implications of the p53 tumour-supressor gene.N Eng J Med. 1993; 329: 1319-1327
- The frequency of p53 immunostaining in asbestos-associated mesotheliomas and non-asbestos associated mesotheliomas.Histopathology. 1993; 22: 383-386
- P53 immunostaining in the differentiation of reactive processes from malignancy in pleural biopsy specimens.Hum Pathol. 1993; 25: 443-448
- Immunoreactivity for p53 protein in malignant mesothelioma and nonneoplastic mesothelium.J Pathol. 1992; 168: 371-375
- p53 expression in malignant mesothelioma.Histopathology. 1992; 21: 331-334
- Simian virus-40 large T antigen binds p53 in human mesotheliomas.Nat Med. 1997; 3: 908-912
- Immunohistochemical staining of ras oncogene product in neoplastic and non neoplastic mesothelial tissues: immunoreactivity for N-ras and lack of immunohistochemical staining for Ha-ras and K-ras.J. Pathol. 1993; 169: 421-424
- Molecular biology studies on mesothelioma tumour samples: preliminary data on H-ras, p21 and SV40.J Environ Pathol Tox Oncol. 1995; 14: 29-34
- Significance of metallothionein overexpression in human tumors.Histopathology. 1997; 31: 211-214
- Modulation of residence to anticancer drugs by inhibition of metallothionein synthesis.Cancer Res. 1994; 54: 5255-5257
- Multifactorial molecular mechanisms are involved in resistance of preradiated human cervix carcinoma cells to cis-dichlorodiamminoplatinum (II) and vincristine.Neoplasma. 1993; 40: 97-101
- Modulation of both cisplatin nephrotoxicity and drug resistance in murine bladder tumor by controlling metallothionein synthesis.Cancer Res. 1993; 53: 1829-1832
- Immunohistochemical expression of metallothionein in normal human colorectal mucosa, in adenocarcinomas and their associated metastates.Histopathology. 1996; 29: 347-354
- An epidemiological study in an Anatolian village in Turkey environmentally exposed to tremolite asbestos.J Environ Pathol Toxic Oncol. 1996; 15: 177-182
- Assessment of environmental asbestos exposure in Turkey by bronchoalveolar lavage.Am J Respir Crit Care Med. 1998; 158: 1815-1824
Article info
Publication history
Accepted:
March 27,
2001
Received:
March 20,
2000
Identification
Copyright
© 2001 Harcourt Publishers Ltd. Published by Elsevier Inc.
User license
Elsevier user license | How you can reuse 
Elsevier's open access license policy
Elsevier user license
Permitted
For non-commercial purposes:
- Read, print & download
- Text & data mine
- Translate the article
Not Permitted
- Reuse portions or extracts from the article in other works
- Redistribute or republish the final article
- Sell or re-use for commercial purposes
Elsevier's open access license policy
